Manufacturer cash-pay prescription platforms Market Outlook 2026–2033: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines manufacturer cash-pay prescription platforms, where drug makers sell prescription medicines straight to self-paying patients through their own online pharmacies or through telehealth, retail and mail order partners at a published monthly price. It tests how far cash-pay becomes a standard channel beside insurance and Medicare by 2033, and what that means for manufacturers, payers and pharmacies.

Volume is growing as price falls. Eli Lilly and Company reported third quarter 2026 Zepbound sales of USD 5.35 billion worldwide, up 49%, while realized prices across the company fell 15% and sales volume rose 53%. The conclusion is that lower prices are buying much larger volume, and the direct channel is a route to patients that insurance coverage alone did not open.

The platform already has scale. Lilly told investors on 4 February 2026 that its direct-to-patient platform LillyDirect had reached 1 million US patients in 2025, in a year when company revenue rose 45% to USD 65.2 billion. The conclusion is that a manufacturer owned channel can reach a million patients within a few years of launch, and it is large enough to matter to company results.

Government agreements have set the price. Lilly and Novo Nordisk A/S agreed in November 2025 with the US administration to sell Wegovy and Zepbound to eligible cash-paying patients at USD 499 per month for most doses, and TrumpRx.gov went live on 5 February 2026 with more than 40 drugs. The conclusion is that cash prices are now published and public, and a government site points patients to manufacturer platforms.

Prices keep falling at the entry point. The oral drug Foundayo (orforglipron) was approved by the US Food and Drug Administration in April 2026 with self-pay prices from about USD 149 per month for lower doses, available through LillyDirect, telehealth providers and pharmacies. The conclusion is that the first cash price of a new obesity drug now sits far below the former list price of injectables, and new launches are designed for self-pay from day one.

The brief treats manufacturer cash-pay prescription platforms as a high-impact signal with a seven year horizon to 2033. It identifies which manufacturers, pharmacies and payers move first and what each means for price, volume and patient access. It is a focused 108-page decision brief that presents an indicative trajectory rather than a segmented market model.

The core model is a manufacturer platform linked to partner pharmacies. LillyDirect sells Zepbound vials at self-pay prices of USD 299 for 2.5 mg, USD 399 for 5 mg and USD 449 for higher doses when the patient refills within 45 days under the Journey Program, against USD 499 for 7.5 mg and USD 699 for 10, 12.5 and 15 mg without it. The conclusion is that the manufacturer sets the price by dose and by refill behaviour, which rewards patients who stay on treatment.

Government price platforms now route patients to manufacturers. TrumpRx.gov launched on 5 February 2026 with more than 40 drugs from five first companies, AstraZeneca PLC, Eli Lilly and Company, EMD Serono, Novo Nordisk A/S and Pfizer Inc., and ordering a Zepbound vial redirects the patient to LillyDirect. The conclusion is that the government site acts as a front door while fulfilment stays with the manufacturer or its pharmacy partner.

Prices have moved sharply. Wegovy injectable moved from USD 1,349 to an average of USD 350 per month and the Wegovy pill from USD 1,349 to between USD 149 and USD 299 depending on dose, while Zepbound moved from USD 1,088 to an average of USD 346 and as low as USD 299. The conclusion is that cash prices for obesity drugs have fallen by about two thirds within a year, and this reshapes who can afford treatment.

Oral drugs widen the channel. Foundayo is sold through LillyDirect, telehealth providers including Ro and WeightWatchers Med+, pharmacies including Amazon Pharmacy, and GoodRx, with insured patients paying as little as USD 25 per month with savings programmes. The conclusion is that a pill is easier to distribute and stock than a cold chain injectable, and it brings retail and telehealth partners into the same price framework.

The limits are pushback from payers, wholesalers and pharmacies, patient safety and prescribing oversight, and supply and counterfeit risk. The brief tests each limit against the pricing evidence to 2033.

The manufacturer cash-pay prescription platforms market, covering revenue from prescription drugs sold by manufacturers directly to patients through their own or partner cash-pay platforms, measured by annual manufacturer net revenue from direct self-pay sales, and excluding insured and wholesale channel sales, compounded and telehealth-only products, and over-the-counter products, is valued at USD 4–8 billion in 2026 and is projected to reach USD 19.07–38.15 billion by 2033, at a CAGR of 25%.

The 2026 base rests on net revenue from obesity and specialty drugs sold through manufacturer platforms and partner pharmacies at self-pay prices, with LillyDirect and the Novo Nordisk direct channel as the largest examples. Growth then follows the number of patients on cash-pay platforms, the spread of oral drugs and the entry of specialty and rare disease drugs.

The forecast is sensitive to cash price levels, the share of obesity patients who move to Medicare and insurance coverage, and the share of platform sales that is booked by manufacturers and not by partner pharmacies.

Scenarios.

The base case assumes steady growth in patients and drugs on manufacturer platforms, bringing the inflection to about 2029 and a 2033 value near the middle of the range. An accelerated case assumes fast entry of oral drugs and specialty drugs, bringing the inflection to 2028 and lifting the 2033 value to the top of the range. A delayed case assumes broad insurance and Medicare obesity coverage and tighter rules on platforms, moving the inflection to 2031 and holding growth at the bottom of the range.

Growth drivers

• Patient demand for lower out-of-pocket cost.
• Manufacturer need to bypass rebate and coverage barriers.
• Government pricing agreements.
• Growth of uninsured and underinsured patients.

Enablers

• Telehealth and e-prescribing tools.
• Manufacturer and pharmacy contracts.
• Contract and project evidence.
• Manufacturer and telehealth partnerships.

Restraints and barriers

• Price pressure and return on investment.
• Pushback from payers, wholesalers and pharmacies.
• Patient safety and prescribing oversight.
• Differences in national pricing and promotion rules.

The direction of manufacturer cash-pay prescription platforms is set by patient demand for lower out-of-pocket cost, manufacturer need to bypass rebate and coverage barriers, government pricing agreements, telehealth and e-prescribing tools, and the readiness of pharmacies and payers to work with a second channel.

The key participants in manufacturer cash-pay prescription platforms and pharma direct-to-consumer include Eli Lilly and Company, Novo Nordisk A/S, Pfizer Inc., AstraZeneca PLC, Merck KGaA, Merck & Co., Inc., AbbVie Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Amgen Inc., Sanofi, GSK plc, Novartis AG, Roche Holding Ltd, Amazon.com, Inc., Hims & Hers Health, Inc., GoodRx Holdings, Inc., CVS Health Corporation, Teladoc Health, Inc., Cencora, Inc., McKesson Corporation, Cardinal Health, Inc., UnitedHealth Group Incorporated, The Cigna Group, Elevance Health, Inc., Humana Inc., Takeda Pharmaceutical Company Limited, Bayer AG, Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals, Inc., Gilead Sciences, Inc., Vertex Pharmaceuticals Incorporated, Biogen Inc., Teva Pharmaceutical Industries Limited, Viatris Inc., Walmart Inc., Costco Wholesale Corporation, Doximity, Inc., Veeva Systems Inc., the US Food and Drug Administration, the Centers for Medicare & Medicaid Services, the Federal Trade Commission, the Department of Health and Human Services and the European Medicines Agency.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as specialty and oral drug cash-pay reaches scale.

Eli Lilly and Company and Novo Nordisk A/S lead among manufacturers that run direct platforms, Hims & Hers Health, Inc., Teladoc Health, Inc. and Amazon.com, Inc. lead among telehealth and online pharmacy partners, and GoodRx Holdings, Inc. leads among price discovery services. Competitive intensity is rising as more manufacturers join government price platforms and cut cash prices.

Where value migrates.

In 2026 value sits with manufacturers that hold high-demand obesity drugs and run their own platforms. By 2029 it moves toward platforms that add oral drugs, specialty drugs and broad pharmacy and telehealth reach, because patients want one place to order and one published price. By 2033 it settles with cash-pay as a standard channel beside insurance, where price, supply and patient trust carry the margin. Margins hold for manufacturers with high-demand drugs and safe supply, and narrow for those that sell a single drug at a cash price below the cost of serving the patient.

Lower prices, rising volume and government price platforms support growth, while pushback from payers and pharmacies, safety oversight and the move of patients onto Medicare coverage hold back the pace.

Price cuts, coverage changes or tighter promotion rules could slow progress. The brief therefore tracks four indicators: monthly cash price per patient, patients using manufacturer platforms, drugs on cash-pay platforms and the share of manufacturer revenue from direct sales.

Obesity cash-pay platforms first, then specialty and oral drug cash-pay at scale, then standard status for cash-pay as a route to drugs is the expected order of change.